MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).

被引：2

作者：

Lenz, Heinz-Josef

Lee, Fa-Chyi

Yau, Linda

Koh, Han A.

Knost, James A.

Mitchell, Edith P.

Bosanac, Ivan

Mancao, Christoph

Parikh, Aparna

机构：

[1] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[2] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA

[3] Gentech Inc, San Francisco, CA USA

[4] Southern Calif Permanente Grp, Bellflower, CA USA

[5] Illinois Canc Care, Peoria, IL USA

[6] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA

[7] F Hoffmann La Roche Ltd, Basel, Switzerland

[8] Genentech Inc, San Francisco, CA 94080 USA

来源：

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.493

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

493

引用

页数：1